Startseite Kongressberichte 2021 2021 ASCO Annual Meeting Gastrointestinal Cancer Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

ESCORT-1st: A randomized, double-blind, placebo-controlled, phase 3 trial of camrelizumab plus chemotherapy versus chemotherapy in patients with untreated advanced or metastatic esophageal squamous cell carcinoma (ESCC).
 
Rui-hua Xu, Huiyan Luo, Jin Lu, et al.
 Clinical trial information: NCT03691090
 
Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): First results of the CheckMate 648 study.
 
Ian Chau, Yuichiro Doki, Jaffer A. Ajani, et al.
 Clinical trial information: NCT03143153
----------------------------------------------------------------------------------------------------------------------------------------------------------

PRESSCAST: LBA4001, "First results from the CheckMate 648 study evaluating nivolumab plus ipilimumab or nivolumab plus chemotherapy versus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma"

Abstract: First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) versus chemo in advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Expanded efficacy and safety data from CheckMate 649.
 
Markus H. Moehler, Kohei Shitara, Marcelo Garrido, et al.
 Clinical trial information: NCT02872116
SEE ALSO The ASCO Post
----------------------------------------------------------------------------------------------------------------------------------------------------------
Adjuvant nivolumab (NIVO) in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): Expanded efficacy and safety analyses from CheckMate 577.
 
Ronan Joseph Kelly, Jaffer A. Ajani, Jaroslaw Kuzdzal, et al.
Clinical trial information: NCT02743494
 
Neo-AEGIS (Neoadjuvant trial in Adenocarcinoma of the Esophagus and Esophago-Gastric Junction International Study): Preliminary results of phase III RCT of CROSS versus perioperative chemotherapy (Modified MAGIC or FLOT protocol). (NCT01726452).
 
John V. Reynolds, Shaun R. Preston, Brian O'Neill, et al.
Clinical trial information: NCT01726452
 
Multicenter, randomized phase II study of neoadjuvant pembrolizumab plus chemotherapy and chemoradiotherapy in esophageal adenocarcinoma (EAC).
 
Manish A. Shah, Khaldoun Almhanna, Syma Iqbal, et al.
 Clinical trial information: NCT02998268
 
Liposomal irinotecan (nal-IRI) in combination with fluorouracil (5-FU) and leucovorin (LV) for patients with metastatic biliary tract cancer (BTC) after progression on gemcitabine plus cisplatin (GemCis): Multicenter comparative randomized phase 2b study (NIFTY).
 
Changhoon Yoo, Kyu-Pyo Kim, Ilhwan Kim, et al.
Clinical trial information: NCT03524508
 
Hepatic arterial infusion chemotherapy of oxaliplatin plus fluorouracil versus sorafenib in advanced hepatocellular carcinoma: A biomolecular exploratory, randomized, phase 3 trial (The FOHAIC-1 study).
 
Ning Lyu, Ming Zhao;
Clinical trial information: NCT03164382
 
Neoadjuvant transarterial infusion chemotherapy with FOLFOX could improve outcomes of resectable BCLC stage A/B hepatocellular carcinoma patients beyond Milan criteria: An interim analysis of a multi-center, phase 3, randomized, controlled clinical trial.
 
Shaohua Li, Chong Zhong, Qiang Li, Jingwen Zou, et al.
 Clinical trial information: NCT03851913